What is the SymBio Pharmaceuticals Ltd. stock price forecast?

SymBio Pharmaceuticals Ltd. is currently trading at ¥69. View real-time AI analysis on Alpha Lenz.

What is SymBio Pharmaceuticals Ltd. insider trading activity?

View the latest insider trading data for SymBio Pharmaceuticals Ltd. on Alpha Lenz.

What is SymBio Pharmaceuticals Ltd.'s P/E ratio?

SymBio Pharmaceuticals Ltd.'s P/E ratio is -0.7.

SymBio Pharmaceuticals Ltd.

JPX · 4582

¥69-1(-1.43%)Market closed

Ask about SymBio Pharmaceuticals Ltd.'s future dividend policy...

Alpha Chat Insight

“SymBio Pharmaceuticals Ltd. trades at a P/E of -0.7 (undervalued) with modest ROE of -174.6%.”

Ask for details →

Company Overview

SymBio Pharmaceuticals Ltd. is a specialty pharmaceutical company focused on delivering innovative therapeutics in the oncology and hematology fields. Founded in Japan, the company's mission is to address unmet medical needs by developing therapies that offer new hope to patients. SymBio Pharmaceuticals is recognized for its strategic approach to drug development, often collaborating with international partners to leverage cutting-edge research and enhance clinical outcomes. The company is pivotal in advancing treatments for rare and hard-to-treat cancers, thus impacting the healthcare and biotechnology sectors. Through its dedication to research and development, SymBio Pharmaceuticals plays a significant role in expanding therapeutic options available to healthcare providers and patients worldwide, contributing to the global endeavor of combating challenging diseases.

CEOMr. Fuminori Yoshida

Websitehttps://www.symbiopharma.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees108

Company Statistics

FY 2025

Profile

¥3,464,600,538Market Cap

¥1,307,648,000Revenue

0.00Shares Out

108Employees

Margins

72.45%Gross

-354.31%EBITDA

-339.59%Operating

-363.14%Pre-Tax

-365.25%Net

Valuation

-0.73P/E

2.72P/B

2.65EV/Sales

-0.55EV/EBITDA

-0.74P/FCF

Growth (CAGR)

-49.26%Rev 3Yr

-15.23%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-108.11%ROA

-174.65%ROE

-106.60%ROIC

Financial Health

¥2,883,503,000Cash & Cash Equivalents

¥-288,226,000Net Debt

204.03%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“SymBio Pharmaceuticals Ltd. trades at a P/E of -0.7 (undervalued) with modest ROE of -174.6%.”

Ask for details →

Frequently Asked Questions

SymBio Pharmaceuticals Ltd. (ticker: 4582) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 108 employees. Market cap is $3.5B.

The current price is 69 with a P/E ratio of -0.73x and P/B of 2.72x.

ROE is -174.65% and operating margin is -339.59%. Annual revenue is $1.3B.